New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
Kiril Trpkov,Ondrej Hes,Sean R. Williamson,Adebowale J. Adeniran,Abbas Agaimy,Reza Alaghehbandan,Mahul B. Amin,Pedram Argani,Ying-Bei Chen,Liang Cheng,Jonathan I. Epstein,John C. Cheville,Eva Comperat,Isabela Werneck da Cunha,Jennifer B. Gordetsky,Sounak Gupta,Huiying He,Michelle S. Hirsch,Peter A. Humphrey,Payal Kapur,Fumiyoshi Kojima,Jose I. Lopez,Fiona Maclean,Cristina Magi-Galluzzi,Jesse K. McKenney,Rohit Mehra,Santosh Menon,George J. Netto,Christopher G. Przybycin,Priya Rao,Qiu Rao,Victor E. Reuter,Rola M. Saleeb,Rajal B. Shah,Steven C. Smith,Satish Tickoo,Maria S. Tretiakova,Lawrence True,Virginie Verkarre,Sara E. Wobker,Ming Zhou,Anthony J. Gill
DOI: https://doi.org/10.1038/s41379-021-00779-w
IF: 8.209
2021-03-04
Modern Pathology
Abstract:The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature. Key prognostic features for clear cell renal cell carcinoma (RCC) remain WHO/ISUP grade, AJCC/pTNM stage, coagulative necrosis, and rhabdoid and sarcomatoid differentiation. Accrual of subclonal genetic alterations in clear cell RCC including <i>SETD2, PBRM1, BAP1</i>, loss of chromosome 14q and 9p are associated with variable prognosis, patterns of metastasis, and vulnerability to therapies. Recent National Comprehensive Cancer Network (NCCN) guidelines increasingly adopt immunotherapeutic agents in advanced RCC, including RCC with rhabdoid and sarcomatoid changes. Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. For tumors with 'borderline' features between oncocytoma and chromophobe RCC, a term "<i>oncocytic renal neoplasm of low malignant potential, not further classified</i>" is proposed. Clear cell papillary RCC may warrant reclassification as a tumor of low malignant potential. Tubulocystic RCC should only be diagnosed when morphologically pure. MiTF family translocation RCCs exhibit varied morphologic patterns and fusion partners. <i>TFEB</i>-amplified RCC occurs in older patients and is associated with more aggressive behavior. Acquired cystic disease (ACD) RCC-like cysts are likely precursors of ACD-RCC. The diagnosis of renal medullary carcinoma requires a negative SMARCB1 (INI-1) expression and sickle cell trait/disease. Mucinous tubular and spindle cell carcinoma (MTSCC) can be distinguished from papillary RCC with overlapping morphology by losses of chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22. MTSCC with adverse histologic features shows frequent <i>CDKN2A/2B</i> (9p) deletions. <i>BRAF</i> mutations unify the metanephric family of tumors. The term "fumarate hydratase deficient RCC" ("FH-deficient RCC") is preferred over "hereditary leiomyomatosis and RCC syndrome-associated RCC". A low threshold for FH, 2SC, and SDHB immunohistochemistry is recommended in difficult to classify RCCs, particularly those with eosinophilic morphology, occurring in younger patients. Current evidence does not support existence of a unique tumor subtype occurring after chemotherapy/radiation in early childhood.
pathology